CDC14A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16282346	0.54	9/20
SCHEMBL21343390	0.52	9/20
SCHEMBL21862219	0.51	4/20
SCHEMBL1926670	0.50	4/20
SCHEMBL20205417	0.38	4/20
SCHEMBL4552061	0.36	4/20
SCHEMBL13734913	1.00	3/20
SCHEMBL13734961	1.00	3/20
SCHEMBL13737097	1.00	3/20
SCHEMBL15829160	0.88	3/20
SCHEMBL15829181	0.81	3/20
SCHEMBL15829183	0.78	3/20
SCHEMBL15829184	0.78	3/20
SCHEMBL18231232	0.77	3/20
SCHEMBL15829186	0.75	3/20
SCHEMBL15829159	0.74	3/20
SCHEMBL15829167	0.72	3/20
SCHEMBL15829174	0.67	3/20
SCHEMBL15829168	0.66	3/20
SCHEMBL15829166	0.64	3/20

Clinical trials — most relevant to CDC14A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options	PHASE3	COMPLETED
Novel Peptide Vaccination for Patients With Advanced Prostate Cancer	PHASE1/PHASE2	UNKNOWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer	PHASE2	UNKNOWN
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer	PHASE1	COMPLETED
Somatic Mosaicism in Twins Discordant for Childhood Cancer	nan	RECRUITING
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)	nan	COMPLETED
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study	nan	ACTIVE_NOT_RECRUITING
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer	nan	COMPLETED
Tumor Markers in Lung Cancer: DCAMLK-1LK-1	nan	COMPLETED
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy	nan	COMPLETED
Identification of an Asthma Susceptibility Gene on 3P	nan	COMPLETED
A Positional Cloning Study on Schizophrenia	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Multi-Dimensional Genomic Dissection of Ring Chromosome 14 Syndrome	nan	ACTIVE_NOT_RECRUITING
Developing Genetic Education for Smoking Cessation	nan	COMPLETED
PCD New Gene Discovery	nan	COMPLETED
Hereditary Nonpolyposis Colorectal Cancer in Taiwan-Related Genetic Study and Clinical Applications	nan	UNKNOWN
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
Dissect Assembly Rules of SPET12 Complex in the Mammalian Sperm	nan	COMPLETED
Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer	nan	RECRUITING
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve	nan	UNKNOWN
New Signaling Pathway Targeting Systemic Lupus Erythematosus	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDC14A binder may also engage these)

Protein	Name	Similarity
Q6GQT0	—	1.000	Q6GQT0 →
A0A0R4IVA4	—	1.000	A0A0R4IVA4 →
Q9P7H1	—	1.000	Q9P7H1 →
P81299	—	0.998	P81299 →
CDC14B	Dual specificity protein phosphatase CDC14B	0.994	landscape →
Q59NH8	—	0.994	Q59NH8 →
O43166	—	0.993	O43166 →
A6N3Q4	—	0.993	A6N3Q4 →
O43078	—	0.992	O43078 →
Q92562	—	0.992	Q92562 →
P24583	—	0.992	P24583 →
B3M301	—	0.992	B3M301 →
B4NBP4	—	0.991	B4NBP4 →
P40433	—	0.991	P40433 →
G5EFD2	—	0.991	G5EFD2 →
Q9W3D3	—	0.991	Q9W3D3 →
A4D256	—	0.991	A4D256 →
Q9VM91	—	0.990	Q9VM91 →
Q6PFY9	—	0.990	Q6PFY9 →
Q66HD5	—	0.990	Q66HD5 →
Q06321	—	0.990	Q06321 →
Q5JCS6	—	0.990	Q5JCS6 →
A2CEA7	—	0.990	A2CEA7 →
Q1LYM3	—	0.990	Q1LYM3 →
Q8C0T5	—	0.990	Q8C0T5 →
O97143	—	0.990	O97143 →
A8XQD5	—	0.990	A8XQD5 →
Q6E3D4	—	0.990	Q6E3D4 →
Q22712	—	0.990	Q22712 →
I2HAA0	—	0.990	I2HAA0 →